JP2006510669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510669A5 JP2006510669A5 JP2004559315A JP2004559315A JP2006510669A5 JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5 JP 2004559315 A JP2004559315 A JP 2004559315A JP 2004559315 A JP2004559315 A JP 2004559315A JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- age
- patient
- group
- compound selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43140102P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038678 WO2004052227A2 (en) | 2002-12-06 | 2003-12-05 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510669A JP2006510669A (ja) | 2006-03-30 |
| JP2006510669A5 true JP2006510669A5 (https=) | 2006-08-24 |
Family
ID=32507723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559315A Pending JP2006510669A (ja) | 2002-12-06 | 2003-12-05 | 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20040116403A1 (https=) |
| EP (1) | EP1581212A4 (https=) |
| JP (1) | JP2006510669A (https=) |
| CN (1) | CN1717234A (https=) |
| AU (1) | AU2003298917A1 (https=) |
| BR (1) | BR0317026A (https=) |
| CA (1) | CA2505608A1 (https=) |
| MX (1) | MXPA05005240A (https=) |
| WO (1) | WO2004052227A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| AU2005287343A1 (en) * | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| WO2006091796A2 (en) * | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
| CA2681850C (en) * | 2007-04-20 | 2013-07-23 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
| RU2470910C9 (ru) | 2007-06-29 | 2013-05-20 | Акьюсела, Инк. | Соединения, представляющие собой алкинилфенильные производные, для лечения офтальмических заболеваний и расстройств |
| CN103553945B (zh) | 2007-10-05 | 2015-01-07 | 奥克塞拉有限公司 | 用于治疗疾病的烷氧基化合物 |
| WO2009096905A1 (en) * | 2008-01-30 | 2009-08-06 | Agency For Science, Technology And Research | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds |
| US20110028513A1 (en) * | 2008-03-31 | 2011-02-03 | Lang Zhuo | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| US10052299B2 (en) | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| EP2433640B1 (en) | 2010-09-24 | 2020-01-15 | OmniVision GmbH | Composition comprising SOD, lutein and zeaxanthin |
| KR102112087B1 (ko) | 2011-04-26 | 2020-05-18 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| JP6145087B2 (ja) | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| WO2012148930A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| JP6106157B2 (ja) | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 神経変性障害および筋疾患に関与するｐｕｆａ |
| EP2804605A4 (en) | 2012-01-20 | 2015-07-08 | Acucela Inc | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
| EP2911662A4 (en) * | 2012-10-25 | 2016-09-28 | Technion Res & Dev Foundation | METHOD OF TREATING A DISEASE |
| CA2903483A1 (en) | 2013-03-12 | 2014-10-09 | Acucela Inc. | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders |
| EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| IL295783B2 (en) | 2020-02-21 | 2026-03-01 | Retrotope Inc | Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| TW325997B (en) * | 1993-02-02 | 1998-02-01 | Senju Pharma Co | Pharmaceutical composition for preventing and treating retinal diseases |
| US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
| US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| WO1999023097A1 (en) * | 1997-11-03 | 1999-05-14 | Duke University | Substituted porphyrins |
| GB9817845D0 (en) * | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
| ATE312103T1 (de) * | 1999-01-25 | 2005-12-15 | Nat Jewish Med & Res Center | Substituierte porphyrine und deren therapeutische verwendungen |
| EP1439842A4 (en) * | 2001-06-01 | 2009-09-02 | Nat Jewish Med & Res Center | OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE |
-
2003
- 2003-12-05 CN CNA2003801041193A patent/CN1717234A/zh active Pending
- 2003-12-05 BR BR0317026-8A patent/BR0317026A/pt unknown
- 2003-12-05 EP EP03796677A patent/EP1581212A4/en not_active Withdrawn
- 2003-12-05 JP JP2004559315A patent/JP2006510669A/ja active Pending
- 2003-12-05 AU AU2003298917A patent/AU2003298917A1/en not_active Abandoned
- 2003-12-05 CA CA002505608A patent/CA2505608A1/en not_active Abandoned
- 2003-12-05 MX MXPA05005240A patent/MXPA05005240A/es unknown
- 2003-12-05 WO PCT/US2003/038678 patent/WO2004052227A2/en not_active Ceased
- 2003-12-05 US US10/729,213 patent/US20040116403A1/en not_active Abandoned
- 2003-12-05 US US10/534,791 patent/US20060089343A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510669A5 (https=) | ||
| JP2008519047A5 (https=) | ||
| JP2003503454A5 (https=) | ||
| JP2005518433A5 (https=) | ||
| EE200300295A (et) | Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| JP2007536277A5 (https=) | ||
| DE69918296D1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| JP2005537234A5 (https=) | ||
| EP1676512A3 (en) | Skin treatment articles and methods | |
| ATE482708T1 (de) | Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen | |
| BRPI0416796A (pt) | compostos orgánicos | |
| JP2007510667A5 (https=) | ||
| CY1112184T1 (el) | Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii | |
| ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| JP2007537301A5 (https=) | ||
| EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| JP2008540528A5 (https=) | ||
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| DK1864668T3 (da) | Anvendelse af prodrug til okulær, intravitreal administration | |
| JP2005517713A5 (https=) | ||
| UA101961C2 (xx) | Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида | |
| Club et al. | Autism Spectrum Disorders | |
| WO2007019575A3 (en) | Methods for treating b-cell malignancies using taci-ig fusion molecule | |
| JP2006510659A5 (https=) |